Related Experiment Video
Updated: May 12, 2026
04:09
Minimal Invasive Resection of Large Retrosternal Thyroid Goiter
Published on: September 20, 2024
Two cases of fetal goiter
Ashish Saini1, Murli Manohar Reddy, Roopal Panchani
1Department of Endocrinology, Sir Ganga Ram Hospital, Old Rajinder Nagar, New Delhi, India.
Indian Journal of Endocrinology and Metabolism
|April 9, 2013
Summary
Fetal goiters (FG) detected via ultrasound can lead to serious complications like fetal hypothyroidism. Early diagnosis and treatment, including in-utero interventions, are crucial for optimal outcomes.
Area of Science:
- Maternal-fetal medicine
- Pediatric endocrinology
- Diagnostic imaging
Background:
- Anterior fetal neck masses, including fetal goiters (FG), are rare but can cause significant complications.
- The incidence of goitrous hypothyroidism is estimated between 1 in 30,000 to 50,000 live births.
Observation:
- Two cases of fetal goiter (FG) were identified during routine second-trimester antenatal ultrasound.
- One case involved intra-amniotic L-thyroxine treatment, while the second managed with increased maternal thyroxine dosage.
Findings:
- Ultrasound is vital for diagnosing and monitoring fetal goiters (FG).
- In-utero treatment for fetal hypothyroidism, including intra-amniotic L-thyroxine and maternal dose adjustments, can effectively reduce goiter size and manage thyroid function.
- Successful management led to normal growth and development in neonates.
Implications:
- Emphasizes the critical role of ultrasound in the diagnosis and management of fetal goiters (FG).
- Highlights the availability and efficacy of in-utero treatment options for fetal hypothyroidism.
- Advocates for prioritizing non-invasive procedures and advanced ultrasonography for improved specificity and safety.
Related Concept Videos
01:27Goiter
Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...